Search

The article from Universita Cattolica del Sacro Cuore offers new insights into ischemic optic neuropathy, focusing on the role of carotid artery disease (CAD) in this condition. Topics discussed include the association between CAD and non-arteritic anterior and posterior ischemic optic neuropathies, the methodologies used for reviewing related studies, and the overall impact of CAD on the development of these optic neuropathies.

The article explores the effects of different sequences of aerobic and resistance training on various health parameters in patients with Type 2 Diabetes Mellitus (T2DM) and cardiac autonomic neuropathy. Topics include the impact of training sequences on heart rate variability, glycemic control, body composition, and lipid profile, as well as the overall effectiveness of concurrent training in managing T2DM.

The article reports that the peripheral neuropathic pain market is projected to grow at a compound annual growth rate (CAGR) of 4.1 percent by 2034, according to DelveInsight's latest analysis. Topics discussed include the market size and growth forecasts, key emerging therapies and their expected impact, and the leading companies involved in developing new treatments for peripheral neuropathic pain.

The article reports that Find Therapeutics Inc. has received U.S. Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) application, allowing the company to start a Phase 1 clinical study of FTX-101 for Chronic Optic Neuropathy (CON). Topics discussed include the FDA's approval of the IND application, the planned Phase 1 study of FTX-101, and the potential of FTX-101 as a new therapy for an unmet medical need.

A recent report from the University of Texas McGovern Medical School discusses the use of gabapentinoids as an alternative to opioids for the treatment of neuropathic pain. The researchers found that gabapentinoids can amplify the effects of opioids, increasing pain relief but also potentially leading to overdose-related adverse outcomes. They discovered that gabapentinoids restore normal sensitivity to opioids and reduce hyperexcitability in sensory neurons after spinal cord injury by inhibiting voltage-gated calcium channels. The study suggests that other inhibitors targeting these channels may also enhance opioid treatment for neuropathic pain. [Extracted from the article]

A recent study conducted by researchers from the Medical College of Wisconsin explores the effects of chronic pain on opioid-seeking behavior in mice. The study found that chronic pain increased oxycodone-seeking behavior and intrinsic excitability in non-ensemble neurons in the dorsomedial prefrontal cortex (dmPFC) of female mice, but had no impact on male mice. These findings support clinical reports that chronic pain can promote drug craving and relapse, suggesting that chronic pain itself may lead to neuroadaptations that promote opioid seeking. The study provides valuable insights into the relationship between chronic pain and opioid misuse. [Extracted from the article]

A recent study conducted at National Cheng Kung University Hospital explored the use of sciatic nerve stimulation (SNS) to alleviate neuropathic pain (NP) and reduce neuroinflammation in a rodent model. The researchers focused on the role of satellite glial cells (SGCs) in the dorsal root ganglia (DRG) in the development of NP. They found that SGCs were hyperactivated and expressed ion channels related to NP after nerve injury. SNS was found to suppress SGC hyperactivation, reduce the expression of NP-related ion channels, and induce a shift in macrophage polarization, ultimately alleviating NP and associated neuroinflammation in the DRG. This study highlights the potential of SNS as a neuromodulation technique for managing NP. [Extracted from the article]

A study conducted by researchers at Virginia Commonwealth University has found that FTY720/Fingolimod, a drug that targets sphingosine-1-phosphate receptor 1 (S1PR1), can alleviate paclitaxel-induced neuropathic pain and enhance the efficacy of chemotherapy in the treatment of triple-negative breast cancer (TNBC). Paclitaxel is a commonly used chemotherapy drug for TNBC, but it often causes painful peripheral neuropathy as a side effect. The study showed that FTY720/Fingolimod reduced neuropathic pain, astrocyte activation, and synapse formation in mice, and also enhanced the anti-tumor effects of paclitaxel. These findings suggest that targeting the S1P/S1PR1 axis with FTY720/Fingolimod could be a promising therapeutic strategy for alleviating neuropathic pain and improving the outcomes of chemotherapy in TNBC treatment. [Extracted from the article]

A recent study from Nanchang University in Jiangxi, China explores the application of cell transplantation in the treatment of neuropathic pain (NPP). The researchers discuss the potential of cell therapy in relieving NPP by promoting nerve regeneration and repair. They highlight the use of various cell types, such as Schwann cells, olfactory ensheathing cells, neural stem cells, and mesenchymal stem cells, in preclinical and clinical studies. The study concludes by discussing the challenges and future directions of cell transplantation as a treatment for NPP. [Extracted from the article]

A recent study conducted by Guangzhou Medical University in China has explored potential treatment options for Leber's hereditary optic neuropathy (LHON), a mitochondrial disease that affects the optic nerve. The researchers reprogrammed LHON urine cells into induced pluripotent stem cells (iPSCs) and differentiated them into neural progenitor cells (NPCs) and neurons for disease modeling. Through co-culturing LHON iPSC-derived NPCs with mesenchymal stem cells (MSCs), the researchers observed a significant improvement in mitochondrial function in LHON neurons. This discovery holds promise as a potential therapeutic strategy for LHON patients. [Extracted from the article]

A recent study conducted at Tongji Medical College in Hubei, China, explored the potential benefits of fargesin (Far) in the treatment of neuropathic pain. Neuropathic pain is a chronic condition that significantly impacts patients' lives. The researchers found that Far treatment reversed the decrease in cell viability caused by lipopolysaccharide (LPS) stimulation and offset the negative effects of LPS on M2 polarization. Far also facilitated gene expressions associated with M2 polarization and rescued the changes triggered by LPS in the nuclear factor kappa-B (NF-kappa B) pathway. This study provides new insights into the potential use of Far in neuropathic pain treatment. [Extracted from the article]

A report from the University of Heidelberg discusses the potential risks of using cosmetics during pregnancy and their impact on the development of congenital enteric neuropathies. The research highlights that certain chemical substances found in cosmetics, such as microplastics, benzophenones, parabens, phthalates, and metals, can disrupt and damage the nervous system. These neurotoxins can cross the placental barrier and affect the developing embryo, as well as be secreted in breast milk, exposing babies to them for longer periods. Understanding the mechanisms and role of these chemicals in neurotoxicity is important for determining the safety of using cosmetic products during pregnancy. [Extracted from the article]

A systematic review conducted by researchers at the University of California San Diego (UCSD) evaluated the potential of psilocybin, a Schedule I substance, in the treatment of chronic pain. The review included 28 relevant studies and found that while there is promise for the use of psilocybin in chronic pain relief, the majority of the included studies were of low or very low quality. The researchers concluded that further investigations with standardized protocols are needed to better understand the potential of psilocybin in chronic pain management. This research has been peer-reviewed and published in Regional Anesthesia & Pain Medicine. [Extracted from the article]

A recent study conducted at Rothschild Foundation Hospital in Paris, France, explored the relationship between refractive errors, such as myopia, and glaucoma screening. The researchers found that in highly myopic eyes, a large disk, a large parapapillary delta zone, and a long axial length can be used as screening criteria to detect glaucomatous optic neuropathy. However, in the range from hyperopia to moderate myopia, refractive error is not a strong risk factor for glaucoma. The study also highlighted the importance of considering morphological parameters, such as optic disk size and parapapillary delta zone, in screening for glaucoma in highly myopic eyes. [Extracted from the article]

Researchers in Belo Horizonte, Brazil have conducted a study on the analgesic effects of cannabidiol (CBD) in treating neuropathic pain. CBD, a component of cannabis, has gained interest in the scientific community for its potential to treat anxiety and epilepsy. The study found that CBD administered systemically produced dose-dependent antinociception in mice with neuropathic pain. The analgesic effect was mediated by the activation of the PI3K gamma pathway, nitric oxide, and subsequent direct S-nitrosylation of KATP channels on peripheral nociceptors. This research provides valuable insights into the potential therapeutic applications of CBD in pain management. [Extracted from the article]

A case study conducted by Ohio University explores the condition known as slimmer's paralysis or peroneal nerve neuropathy, which can occur in patients following rapid weight loss. The study focuses on a 49-year-old female who experienced unilateral foot drop after losing a significant amount of weight over six months while taking a GLP-1 receptor agonist for obesity management. The patient was diagnosed and treated conservatively for peroneal nerve compression related to the weight reduction and crossing of legs due to the loss of the fat pad surrounding the fibular nerve. The research has been peer-reviewed and can be accessed through The Journal for Nurse Practitioners. [Extracted from the article]

A recent report from the University of Alabama Birmingham discusses research on sensory chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a type of autoimmune disease affecting the nervous system. The study found that immunotherapy was effective in improving symptoms in 85% of patients who required it. Sensory CIDP was diagnosed based on specific criteria, including chronic progressive or relapsing sensory polyneuropathy and evidence of demyelinating neuropathy. The researchers concluded that sensory CIDP should be recognized as a treatable variant of CIDP. [Extracted from the article]

The article discusses a study by researchers from Florida International University on brachial plexus neuropathy. Topics include the use of ultrasound-guided supraclavicular brachial plexus block for pain relief, the benefits of this block in managing postoperative neuropathy, and the effectiveness of physical therapy following the procedure.

A recent study conducted at Zhejiang Provincial People's Hospital in Hangzhou, China, has provided new insights into ischemic optic neuropathy (ION), a common eye disease that can lead to blindness. The researchers classified ION into two types: anterior ischemic optic neuropathy (AION) and posterior ischemic optic neuropathy (PION), based on the presence or absence of optic disc edema. They also highlighted the importance of early detection and treatment of arteritic ION, which can cause severe complications. The study aims to improve the diagnosis and management of ION to enhance patient outcomes. [Extracted from the article]

Recent research from the Department of Pharmacology in Belo Horizonte, Brazil, highlights the potential of cannabidiol (CBD) to treat anxiety and epilepsy. Unlike delta-9-tetrahydrocannabinol (THC), CBD does not have psychotomimetic effects. The study found that CBD has anti-inflammatory properties and can be used to treat certain types of inflammatory and neuropathic pain. The research concluded that CBD induces systemic analgesia through the activation of the PI3K gamma/NO/KATP signaling pathway in neuropathic mice. [Extracted from the article]

A recent study conducted at St. Louis University examined small fiber neuropathy and the challenges it presents for diagnosis and treatment. The researchers focused on identifying autoantibodies associated with the condition, specifically tri-sulfated heparin disaccharide (TS-HDS) and fibroblast growth factor receptor 3 (FGFR3). They analyzed data from 172 small fiber neuropathy patients and found that TS-HDS and FGFR-3 display distinct characteristics and may be valuable markers for different clinical phenotypes. The study highlights the importance of understanding these markers in order to improve diagnosis and treatment of small fiber neuropathy. [Extracted from the article]

A recent study conducted by researchers at Shanghai Jiao Tong University explored the relationship between age and pain sensitivity in mice with chronic constriction injury (CCI). The study found that older mice experienced more severe and long-lasting pain compared to younger mice. The researchers discovered that the expression of a protein called spinal receptor-active modification protein 1 (RAMP1) was reduced in older mice, but significantly increased after CCI. When RAMP1 was knocked down, the pain sensitivity in adult mice decreased, and CCI-induced pain in older mice was reduced. The findings suggest that RAMP1 plays a role in regulating pain sensitivity in an age-dependent manner, and interfering with RAMP1 could be a potential strategy for alleviating chronic pain in older individuals. [Extracted from the article]

A new report from researchers at Panzhihua Central Hospital in China explores the use of siRNA-based therapy for neuropathic pain. The study focuses on the role of bone morphogenetic protein (BMP) 10 in astrocytic activation, a process that contributes to central sensitization of pain. The researchers found that BMP10 levels were increased in the spinal dorsal horn of mice with neuropathic pain, and targeting BMP10 with siRNA reduced pain hypersensitivity and astrocytic activation. The study suggests that the BMP10/ALK2/Smad1/5/8 signaling pathway plays a key role in pain hypersensitivity after peripheral nerve injury. [Extracted from the article]

Researchers from Mashhad University of Medical Sciences in Iran conducted a study on the analgesic effect of apricot kernel oil on neuropathic pain in rats. The study found that apricot kernel oil, known for its anti-inflammatory and antioxidant effects, could potentially attenuate neuropathic pain. The researchers administered apricot kernel oil and gabapentin to rats with induced neuropathic pain and observed a decrease in nociceptive pain threshold and attenuation of spinal cord biochemical changes. These findings suggest that apricot kernel oil may have potential as a treatment for neuropathic pain due to its anti-inflammatory and antioxidant properties. [Extracted from the article]